Shelton Funds has released its latest N-MFP3 report, providing insights into its financial health and liquidity position as of October 31, 2026. This filing is significant as it reflects the company's ongoing commitment to transparency and stability in the investment management sector.
The report highlights that Shelton Funds manages The United States Treasury Trust, a government money market fund. This fund is designed to provide investors with a safe and liquid investment option, especially in uncertain economic times.
Background
Shelton Funds, identified by its Central Index Key (CIK) 0000778206, operates within the investment management industry. The company has undergone name changes in the past, previously known as California Investment Trust. It is currently based in Denver, Colorado, and has been active in filing various reports with the SEC, including its recent N-MFP3 on November 5, 2026.
What the Filing Says
The N-MFP3 filing reveals that Shelton Funds has a total value of daily liquid assets amounting to approximately $22,122,179.67, indicating a robust liquidity position. The filing states, "The average portfolio maturity is 52 days," which suggests a focus on maintaining liquidity while managing risk effectively.
Impact
This update may affect investors and stakeholders who rely on the fund's performance metrics and liquidity status. With its strong liquid assets, Shelton Funds positions itself favorably against competitors in the government money market fund sector, ensuring it can meet investor demands efficiently.
What's Next
The filing does not specify what happens next, but it underscores the company's ongoing commitment to maintaining transparency and stability in its operations.
Read Next
Lord Abbett Money Market Fund Reports Stable Financials
Columbia Funds Series Trust II Files Latest N-CEN Report
ProShares Trust files N-MFP3 report on GENIUS ETF
Blue Ocean ATS Amends Fair Access Rule Compliance Details
WisdomTree Digital Trust Reports Strong Liquid Assets
FMR LLC acquires 6.4% stake in Tarsus Pharmaceuticals









